Work

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: Final analysis of a multicentre, open-label, single-arm, phase 2 trial

Year: 2020

Type: article

Source: Gynecologic Oncology

DOI: 10.1016/j.ygyno.2020.06.012

Authors: V. Makker, D. Rasco, N. Vogelzang, M. Brose, A. Cohn, J. Mier, C. DiSimone, D.M. Hyman, D. Stepan, C. Dutcus, E. Schmidt, M. Guo, P. Sachdev, R. Shumaker, C. Aghajanian, M. Taylor

Institutions: Memorial Sloan Kettering Cancer Center, South Texas Accelerated Research Therapeutics, Comprehensive Cancer Centers of Nevada, University of Pennsylvania, Rocky Mountain Cancer Centers, Beth Israel Deaconess Medical Center, Arizona Oncology, Eisai (United States), Merck & Co., Inc., Rahway, NJ, USA (United States), OHSU Knight Cancer Institute

Language: English

Topic: Endometrial and Cervical Cancer Treatments

Subfield: Obstetrics and Gynecology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4248035133

FWCI: 0.459

Cites:

Cited by: 4

Related to: 10